Tissue Distribution, Histopathological and Genotoxic Effects of Magnetite Nanoparticles on Ehrlich Solid Carcinoma

Heba Bassiony1 · Akmal A. El‑Ghor1 · Taher A. Salaheldin2 · Salwa Sabet1 · Mona M. Mohamed1,3

Received: 18 November 2021 / Accepted: 2 January 2022 / Published online: 15 January 2022
© The Author(s) 2022

Abstract
Nanoparticles can potentially cause adverse effects on cellular and molecular level. The present study aimed to investigate the histopathological changes and DNA damage effects of magnetite nanoparticles (MNPs) on female albino mice model with Ehrlich solid carcinoma (ESC). Magnetite nanoparticles coated with L-ascorbic acid (size ~ 25.0 nm) were synthesized and characterized. Mice were treated with MNPs day by day, intraperitoneally (IP), intramuscularly (IM), or intratumorally (IT). Autopsy samples were taken from the solid tumor, thigh muscle, liver, kidney, lung, spleen, and brain for assessment of iron content, histopathological examination, and genotoxicity using comet assay. The liver, spleen, lung, and heart had significantly higher iron content in groups treated IP. On the other hand, tumor, muscles, and the liver had significantly higher iron content in groups treated IT. MNPs induced a significant DNA damage in IT treated ESC. While a significant DNA damage was detected in the liver of the IP treated group, but no significant DNA damage could be detected in the brain. Histopathological findings in ESC revealed a marked tumor necrosis, 50% in group injected IT but 40% in group injected IP and 20% only in untreated tumors. Other findings include inflammatory cell infiltration, dilatation, and congestion of blood vessels of different organs of treated groups in addition to appearance of metastatic cancer cells in the liver of non-treated tumor group. MNPs could have an antitumor effect but it is recommended to be injected intratumorally to be directed to the tumor tissues and reduce its adverse effects on healthy tissues.

Keywords Magnetite nanoparticles · Histology · Ehrlich tumor · DNA damage · Mice

Introduction
Toxic effects of nanoparticles depend on their exposure route, exposure duration, and physicochemical properties such as size, shape, reactivity, and material composition [1, 2]. Studies conducted on iron oxide nanoparticles had controversial results. For instance, a study suggested non-toxicity of iron oxide nanoparticles under in vivo condition whereas others reported minimal toxicity or severe cell death [3–5]. Magnetite nanoparticles (MNPs) have been used in biomedical applications including delivery of drugs or genes, labeling of macromolecules and cells, tissue engineering, magnetic transfection, chelation therapy, and in the destruction of tumor tissue through hyperthermia [6–8]. Therefore, evaluation of the health impact of iron oxide nanoparticles is important [9]. Several studies have reported MNP-induced cytotoxicity. MNPs showed toxicity on rat liver-derived cell line (BRL3A) at high concentration. Moreover, super paramagnetic iron oxide NPs caused toxic effect with repeated injections in rats, rabbits, dogs, and...
monkeys [10]. Dextran-MNPs and uncoated MNPs caused cell death and reduced proliferation of fibroblasts in vitro [11]. Another study demonstrated that iron oxide NPs caused moderate cytotoxicity on Vero cell line [12].

MNPs caused hyperthermia-mediated cell death due to oncocytic necrosis in a mouse xenograft model of a human head and neck squamous cell carcinoma cell line (Tu212) [13]. Another study showed that MNPs combined with daunorubicin were highly biocompatible and safe nanoparticles, suitable for the treatment of hematologic malignancies and were able to overcome multidrug resistance in mice [14].

Minor variations in histology of both the spleen and liver were observed at high concentrations, i.e., 200 × higher doses than that used for MR imaging [15, 16]. Single intratracheal instillation of MNPs in mice caused chronic inflammatory responses through microgranulomatous changes in the alveolar space [17]. However, rats exposed to single intratracheal instillation of MNPs revealed no abnormalities in the liver, kidneys, and spleen, whereas the lungs developed a weak pulmonary fibrosis. As well as MNPs caused injury of cell membranes of both animal and human lung cells that became irregular and lost continuity, and finally, the cells were fragmented [12, 18].

Intravenous injection of MNPs stabilized by 2, 3-dimercaptosuccinic acid (DMSA) in mice formed clusters of MNPs in blood vessels, increased number of leukocytes in the organs, and induced pulmonary fibrosis in the lung. After 90 days of injection, lung parenchyma became normal, except for a few cells that contained MNPs and small groups of inflammatory cells [19].

In addition, nanoparticles can gain access to the nucleus and induce genotoxic effect [20]. Swiss mice, treated with MNPs coated with polyaspartic acid, showed increase in micronucleus frequency [21, 22]. The present study aimed to investigate the histopathological effects and induction of DNA damage by MNPs coated with L-ascorbic acid on ESC and normal tissue that may give insight into the toxicological mechanism of application of nanoparticles. Also, this study aimed to assess the tissue distribution of MNPs in ESC bearing mice.

Materials and Methods

Preparation and Characterization of Magnetite Nanoparticles (MNPs)

MNPs capped with L-ascorbic acid with 25.0 ± 5.0 nm size were synthesized by co-precipitation. In this method, 0.25 g of FeCl₃ anhydrous was dissolved in 25 mL sterile saline. Then, 10 mL of 6 M Na₂CO₃ was added drop by drop with continued stirring for 10 min; the solution turned brown color. Then 0.12 g ascorbic acid was added with vigorous stirring for 15 min; the color of solution turned black. Finally, the solution was completed to 50 mL with sterile saline and sterilized by autoclaving [23]. Physicochemical properties of MNPs were characterized using High-Resolution Transmission Electron Microscope (HR-TEM, FEI, Tecnia G20), Particle size analyzer (Malvern, ZS), and X-ray Diffraction (XRD, PanAnalytical, X’pert Pro) [24, 25].

Mice Treatment

Study protocol was approved by the Institutional Animal Care and Use Committee (IACUC), Faculty of Science, Cairo University, Egypt (approval number: CUFS/F/Cell Biol/02/13). All the experimental procedures were carried out in accordance with international guidelines for care and use of laboratory animals as described before [23, 26].

Six-week-old female Swiss albino mice with body weight 25–30 g were obtained from animal house of National Cancer Institute, Cairo University, Egypt. Upon arrival, mice were randomly transferred to plastic cages containing sawdust bedding and allowed to acclimatize for 2 weeks before the start of the experiment. They were housed under the standard conditions of room temperature (22–24 °C), humidity (45–65%), light (12 h light/12 h dark cycles), and received food and tap water ad libitum.

Ehrlich ascites carcinoma bearing mouse was obtained from National Cancer Institute (Cairo, Egypt). Viability of cells was estimated by staining with Trypan blue dye and counting with Neubauer hemocytometer, as previously described by Dagli et al., 1992 [27, 28]. Mice were randomly divided into six groups (six mice/group), control untreated, IP MNPs, IM MNPs, ESC, ESC + IP MNPs, and ESC + IT MNPs (where IP = intraperitoneally injected with MNPs, IM = intramuscularly injected with MNPs, and IT = intratumorally injected with MNPs).

For tumor induction, mice of groups 4, 5, and 6 were implanted with 0.2 mL of Ehrlich tumor cell suspension (containing about 2 × 10⁶ viable cells) IM in the thigh of the left hind leg. Once solid tumor appeared on the day 14 (time taken for detectable mass of tumor to appear depends on the amount and viability of the injected cells, mostly 12–14 days after initial injection), mice in groups 2, 3, 5, and 6 were injected with 60 mg/kg of MNPs day by day for fourteen injections. Groups that were not injected with MNPs were injected with saline (groups 1 and 4). Finally, animals were sacrificed by cervical dislocation after being anesthetized using sodium thiopental (0.5%). Autopsy samples were taken from the tumor, thigh muscle, liver, kidney, lung, spleen, and brain for subsequent analyses. Part of the samples was preserved in 10% formaldehyde for histopathological examination, while another part was preserved in −80 °C for assessment of iron content, and comet assay.
Measurement of Iron Bio-Distribution

Tissue samples from the tumor, thigh muscle, liver, kidney, lungs, spleen, heart, and brain weighing 100–900 mg (mean 300 ± 20 mg) were dried in the muffle to form ash. The ash was digested with concentrated hydrochloric acid, then was diluted with distilled water and was filtered to get rid of impurities. Iron concentration was estimated using inductively coupled plasma optical emission spectrometry ICP-OES (Thermo Scientific™ iCAP™ 7000) [29, 30]. The amount of iron was calculated from the linear portion of the generated standard curve [31].

Histological Analysis

Samples were taken from the ESC, liver, kidney, lung, spleen, and brain and were fixed in 10% formal saline for 24 h. Then were dehydrated in ascending series of alcohol, cleared in xylene, and embedded in paraffin wax at 56 °C for 24 h. Paraffin sections of 4-µm thickness were collected on glass slides, dewaxed in xylene, hydrated in descending series of alcohol, stained by hematoxylin and eosin stains, dehydrated in ascending series of ethyl alcohol, cleared in two changes of xylene, and mounted with DPX. Finally, slides were examined by light electric microscope (Olympus, CX41, Japan).

DNA Damage Analysis by Comet Assay

DNA damaging effects of MNPs on tumor, muscle, liver, and brain tissues were investigated using the single cell gel electrophoresis (SCGE) or called alkaline comet assay [32]. Slides were prepared using 10 µl of cell suspension and 70 µl of 0.5% low melting agarose (Thermo scientific, USA) and spread on a fully frosted slide pre-dipped in 1% normal melting agarose. Slides were incubated in cold lysis buffer (2.5 M NaCl, 100 mM EDTA, and 10 mM Trizma base, pH 10, with freshly added 1% Triton X-100 and 10% DMSO 30 min before use) for 24 h at 4 °C in darkness. Slides were washed for 10 min in deionized H$_2$O, incubated for 20 min in electrophoresis alkaline buffer (300 mM NaOH and 1.0 mM EDTA, pH 13) to allow unwinding of the DNA and electrophoresed for 20 min at 300 mA and 25 V (0.90 V/cm). Then slides were neutralized in 0.4 M Tris, pH 7.5, fixed in 100% cold ethanol, and stained with ethidium bromide (0.2 µg/mL). The comets were observed using Nikon epifluorescence microscope (filter B-3A; excitation: $\lambda = 420 – 490$ nm; emission: $\lambda = 520$ nm) at a magnification of 400 ×. For each sample, 50 cells were scored using Comet 5 image analysis software developed by Kinetic Imaging, Ltd. (Liverpool, UK).

Statistical Analysis

Data were analyzed using statistical package for the social sciences software (SPSS) version 20.0. Student’s $t$-test or analysis of variance (ANOVA) was used to illustrate the comparison of iron distribution, percentage of DNA in comet tail in different tissues among groups and followed by Duncan multiple comparison test to determine differences among groups. The results are presented as mean ± standard error (SE) for three samples for each group. $P$-value < 0.05 was considered as statistical significance.

Results

Properties of MNPs

Physicochemical properties of synthesized MNPs were characterized via different techniques as have been described before [23]. As shown in Fig. 1, HR-TEM revealed that synthesized MNPs have homogeneous size 25.0 ± 5.0 nm, spherical in shape, and loosely agglomerated with single-crystal. Particle size distribution obtained by dynamic light scattering (DLS) showed that the hydrodynamic average size of MNPs is 25.8 nm. XRD phase analysis confirmed the phase formation of Fe$_3$O$_4$ crystal.

Iron Bio-Distribution in Different Organs

Measurements of iron concentrations in micrograms per gram of dry organ weight of triplet samples are presented as mean ± standard error of mean (SE) in Table 1 and presented in Fig. 2.

As shown, mice groups treated IP with MNPs and IP with MNPs + ESC have highest accumulation of iron in their organs in comparison to other groups. The highest iron concentrations of these groups were detected in the liver (5972.46 ± 61.2 and 7032.3 ± 108.6 µg/g, respectively), spleen (4542.1 ± 107.3 and 4719.4 ± 72.9 µg/g, respectively), and lung (4530.42 ± 149.6 and 5158.4 ± 39.0 µg/g, respectively).

On the other hand, groups treated locally (IT and IM) with MNPs have highest iron concentration in their ESC and muscles. There is no significant difference in iron concentrations in organs of mice treated only with MNPs compared to the control group.

Statistically significant difference was found in the distribution of iron in ESC among groups with highest iron concentration in ESC treated IT with MNPs (3120.5 ± 68.7 µg/g) (Fig. 2f).

In muscles, group treated IM with MNPs showed the highest accumulation of iron compared with other groups (6395.4 ± 110.8 µg/g) (Fig. 2c).
The highest accumulation of iron in liver was found in IP treated groups with MNPs, with no significant difference between them (6032.3 ± 95.6 and 5972.46 ± 61.2 µg/g respectively) but are significantly different from the other groups (Fig. 2b, e).

Similarly, the highest accumulation of iron in the spleen was observed in IP treated groups with MNPs, IP
MNPs, and ESC + IP MNPs. They have similar and significantly higher concentration of iron (4719.4 ± 72.9 and 4542.1 ± 107.3 µg/g respectively) (Fig. 2b, e) compared to the control group (2001.4 ± 75.4 µg/g) (Fig. 2a).

IP treated group with MNPs and ESC treated IP with MNPs have significantly higher iron concentration in their brain tissues (3131.7 ± 108.6 and 3074.5 ± 110.9 µg/g respectively) compared to the control group (2011.1 ± 97.8 µg/g) (Fig. 2a).

### Table 1: Comparison of iron distribution (µg/g) in different organs among groups

| Group  | Tissue | 1 (control) | 2 (IP MNPs) | 3 (IM MNPs) | 4 (ESC) | 5 (ESC + IP MNPs) | 6 (ESC + IT MNPs) |
|--------|--------|-------------|-------------|-------------|---------|------------------|------------------|
| 1 (control) |  | 650.8 ± 39.6 | 1182.6 ± 76.6 | 3120.5 ± 68.7 |
| 2 (IP MNPs) |  | 1426.8 ± 77.7 | 1981.6 ± 33.4 | 990.7 ± 62.2 | 1343.2 ± 80.1 | 972.7 ± 24.8 |
| 3 (IM MNPs) |  | 1093.1 ± 56.9 | 6032.3 ± 95.6 | 1369.7 ± 20.0 | 5972.46 ± 61.2 | 1663.5 ± 95.1 |
| 4 (ESC) |  | 1960.6 ± 68.1 | 1954.4 ± 49.38 | 1491.6 ± 88.4 | 1899.4 ± 91.6 | 2161.9 ± 128.6 |
| 5 (ESC + IP MNPs) |  | 2042.1 ± 109.9 | 3131.7 ± 108.6 | 2177.8 ± 112.6 | 3074.5 ± 110.9 | 2011.1 ± 97.8 |
| 6 (ESC + IT MNPs) |  | 1350.0 ± 66.8 | 3173.6 ± 111.8 | 1416.7 ± 85.1 | 1342.4 ± 125.6 | 2897.8 ± 120.6 |

All values are represented as mean ± standard error of mean (SE). There is a significant difference between groups by using one-way ANOVA at $P < 0.05$ followed by Duncan multiple comparison test. The same letter means that there is no significant difference between the two groups by using Duncan multiple comparison test ($P > 0.05$). The different letters mean that there is a significant difference between the two groups by using Duncan multiple comparison test ($P < 0.05$). *Statistically significant compared with negative control using Student’s t-test.
respectively) (Fig. 2b, e) compared to the control group (2042.1 ± 105.9 µg/g) (Fig. 2a).

Similarly, lung tissues have the highest concentration of iron in IP treated group with MNPs and ESC treated IP with MNPs (5158.4 ± 39.0 and 4530.4 ± 95.7 µg/g respectively) (Fig. 2b, e). Both have significantly higher iron concentration compared to the control group (Fig. 2a). While the least concentration of iron was found in the control group and mice injected with ESC only (2764.6 ± 86.3 and 2798.1 ± 87.5 µg/g respectively) (Fig. 2a, d).

On the other hand, there was no significant difference in iron concentrations in the brain among groups except for ESC treated IT with MNPs that showed the lowest concentration of iron (966.8 ± 73.4 µg/g) (Fig. 2f).

Finally, for the kidney, the highest concentration of iron was recorded in mice that received IP injection with MNPs (3173.6 ± 111.8 µg/g) (Fig. 2b). In contrast, the least concentration of iron was recorded in mice injected with ESC only (1342.4 ± 125.6 µg/g) (Fig. 2d).

**Histological Examination**

Histopathological examination of ESC shows sheets of small, higher chromatophilic tumor cells of variable shape representing cell proliferation surrounding areas of necrosis and differentiated cells. These tumor cells occupied most of the skeletal muscle bundles and only few areas of necrosis (20%) in non-treated tumor. While necrotic areas significantly increased in tumor groups injected with MNPs, giving that the highest percentage of necrosis was observed in the IT treated group (50%) (Fig. 3).

For the liver, MNPs induce inflammatory cell infiltration between the hepatocytes and slight congestion of the central and portal vein with hepatocyte degeneration compared to the control group. By comparing the tumor groups, focal metastatic cancer cells in the degenerated hepatic parenchyma were found in non-treated tumor group that did not appear in MNP-treated tumor groups (Fig. 4).

For the brain, focal gliosis was observed in the IP treated tumor group which disappeared in the other tumor groups (tumor only and IT treated tumor) (Fig. 5).

For the spleen, the main observation was found in production of massive number of megakaryoblasts in the tumor groups, while the other treated groups show inflammatory cell infiltration in the splenic capsule and lymphoid depletion in the white pulps (Fig. 6).

For the kidney, the main observation was inflammatory cell infiltration in the renal capsule or between the renal tubules in all treated groups except IM injected groups (Fig. 7).

For the lung, the main observation was peribronchiolar or perivascular inflammatory cell infiltration in all treated groups compared to the control group (Fig. 8).

**MNP-Induced DNA Damage in ESC and Liver Tissues**

Genotoxicity study using comet assay was performed on ESC, skeletal muscles, liver, and brain tissues. The extent of DNA damage for all samples was evaluated using DNA percentage in tail that represents the intensity of all tail pixels divided by the total intensity of all pixels in the comet. Figure 9 shows typical nuclei with various degrees of DNA damage that were observed as comet.

By comparing the percentage of DNA in tail that was observed in ESC and skeletal muscles, treatment with MNPs resulted in significant increase in percentage of DNA in comet tail, indicating induction of DNA damage. As shown in Table 2 and Fig. 10, all treated groups have statistically significant increase ($P < 0.05$) in percentage of DNA in tail compared with the control group. Also, it was observed that more DNA damage was induced by local injection of IM treated with MNPs or IT treated with MNPs than IP injection in IP treated mice and IP treated ESC.

By comparing the percentage of DNA in comet tail in liver tissues among groups, a statistically significant difference was found in percentage of DNA in comet tail in the group treated IP with MNPs and ESC treated IP with MNPs (16.7 ± 0.9 and 18.9 ± 1.2, respectively) ($P < 0.05$) compared to control (Table 3, Fig. 11).

On the other hand, no statistically significant difference was found by comparing the percentage of DNA in comet tail in brain tissues among groups ($P > 0.05$). So MNPs may have no effect on DNA of brain tissue (Table 4, Fig. 12).

---

**Fig. 3** Photomicrograph of ESC of mice. a Group 4 showing intact cancer cells (cc) occupying 90% of the skeletal muscle bundles with only 20% necrosis. b Group 5 showing 40% necrosis (nc) of the injected Ehrlich tumor cells. c Group 6 showing 50% necrosis (nc). H&E, 40×
Fig. 4 Photomicrograph of liver sections of mice. a Group 1 (control) showing normal histological structure of the central vein (cv), portal area (p), and surrounding hepatocytes (h). b Group 2 (IP-MNPs) showing dilatation in the central vein (cv) and degeneration in hepatocytes (d). c Group 3 (IM-MNPs) showing dilatation and congestion of the central (cv) and portal vein (p) with degeneration in hepatocytes (d). d Group 4 (ESC) showing focal metastatic cancer cells (cc) in the degenerated hepatic parenchyma (d) with dilatation in the central vein (cv). e Group 5 (ESC + IP-MNPs) showing dilatation in the portal vein (pv) and inflammatory cell infiltration (m) surrounding the bile ducts in portal area and degeneration in hepatocytes (d). f Group 6 (ESC + IT-MNPs) showing inflammatory cell infiltration in between hepatocytes (arrow). H&E, 40×

Fig. 5 Photomicrograph of brain sections of mice. a Group 1 (control) showing normal histological structure of the meninges (m), cerebral cortex (cc), and cerebrum (c). b Group 2 (IP-MNPs) showing intact normal histological structure. c Group 3 (IM-MNPs) showing mild congestion in the cerebral blood vessels (v). d Group 4 (ESC) showing intact normal histological structure. e Group 5 (ESC + IP-MNPs) showing focal gliosis (g) in the cerebrum. f Group 6 (ESC + IT-MNPs) showing massive number of inflammatory cell infiltration in meninges (m). H&E, 40×
Discussion

Nanomaterials have attractive characteristic features than larger particles; they are small enough to cross biological barriers such as the blood vessel walls and cell membrane [33]. Most nanomaterials achieve selective tumor accumulation via the enhanced permeability and retention (EPR) effect or targeting to cellular receptors [34]. It was reported that toxic effects of NPs are controversial and may be dependent on particle size, surface coating, exposure route, and exposure duration [35]. Magnetite nanoparticles (MNPs) have promising approach in tumor detection, screening, and destruction [36, 37].
Regarding the dose, previous in vivo toxicological studies indicated no mortalities in mice treated with MNPs using up to 60 ppm, the same dose that was used in the present study and in an early study (patent co-author TAS) for treating anemia [24]. Previously, the first tolerance study with carbohydrate-coated magnetic nanoparticles as potential delivery systems was performed in nude mice and showed no median lethal dose ($LD_{50}$) after injection of magnetic nanoparticles [38, 39].
Previous results of the authors showed that MNPs enhanced the expression of p53 and p16 genes, tumor suppressor genes, those direct cells to trigger programmed cell death by apoptosis in ESC cells [23].

Herein, after injection of control and tumor-bearing mice with the synthesized MNPs IP and IT, tumor and normal tissue distribution of MNPs was evaluated in normal and tumor-bearing mice. Furthermore, the histopathological effects and DNA damage induced by MNPs in normal and tumor tissues were investigated. This study will give an insight into the possible adverse effects of MNPs on different tissues and organs. It is important to know the biological responses to NPs and their safety when they are circulated, distributed, and accumulated in each tissue during the application. Histopathology studies conducted by different investigators showed that MNPs such as fluorodeoxy glucose–conjugated magnetite nanoparticles (FDG-mNPs) showed different distribution and histological changes in cancer-bearing mice [40]. The magnetic fibrin nanoparticles are highly accumulated in the tissues of the liver and spleen.

### Table 2 Effect of MNP injection on DNA damage induced in ESC and muscle tissues

| Groups                 | Tail length (µm) (mean ± SE) | % DNA in tail (mean ± SE) | Tail moment (µm) (mean ± SE) |
|------------------------|------------------------------|---------------------------|-----------------------------|
| Group 1 (control)      | 5.7 ± 1.4<sup>a</sup>        | 4.8 ± 0.5<sup>a</sup>     | 0.3 ± 0.6<sup>a</sup>       |
| Group 2 (IP MNPs)      | 12.9 ± 2.1<sup>b,c</sup>     | 11.5 ± 1.8<sup>b</sup>    | 1.5 ± 2.0<sup>b</sup>       |
| Group 3 (IM MNPs)      | 13.1 ± 1.7<sup>c</sup>       | 16.3 ± 1.4<sup>c</sup>    | 6.2 ± 0.7<sup>c</sup>       |
| Group 4 (ESC)          | 11.2 ± 1.8<sup>b,c</sup>     | 7.3 ± 0.6<sup>a,b</sup>   | 0.8 ± 0.9<sup>a,b,c</sup>   |
| Group 5 (ESC + IP MNPs)| 9.15 ± 1.0<sup>a,b</sup>     | 9.14 ± 1.2<sup>a,b</sup>  | 0.9 ± 0.2<sup>a,b</sup>     |
| Group 6 (ESC + IT MNPs)| 20.8 ± 0.9<sup>c</sup>       | 31.2 ± 3.2<sup>d</sup>    | 11.2 ± 1.1<sup>c</sup>      |

All values are represented as mean ± standard error of mean (SE). There is a significant difference between groups by using one-way ANOVA at P < 0.05 followed by Duncan multiple comparison test. The same letter means that there is no significant difference between the two groups by using Duncan multiple comparison test (P > 0.05). The different letters mean that there is a significant difference between the two groups by using Duncan multiple comparison test (P < 0.05). *Statistically significant compared with negative control using Student’s t-test.

### Table 3 Effect of MNP injection on DNA damage induced in liver tissues

| Groups                 | Tail length (µm) (mean ± SE) | % DNA in tail (mean ± SE) | Tail moment (µm) (mean ± SE) |
|------------------------|------------------------------|---------------------------|-----------------------------|
| Group 1 (control)      | 4.2 ± 0.7<sup>a</sup>        | 6.4 ± 0.8<sup>a</sup>     | 0.3 ± 0.5<sup>a</sup>       |
| Group 2 (IP MNPs)      | 13.7 ± 1.4<sup>c</sup>       | 16.7 ± 0.9<sup>b</sup>    | 2.3 ± 1.3<sup>b</sup>       |
| Group 3 (IM MNPs)      | 8.4 ± 2.6<sup>a,b</sup>      | 7.4 ± 1.1<sup>a</sup>     | 0.7 ± 0.9<sup>a</sup>       |
| Group 4 (ESC)          | 6.4 ± 0.8<sup>a,b</sup>      | 7.2 ± 0.2<sup>a</sup>     | 0.5 ± 0.3<sup>a</sup>       |
| Group 5 (ESC + IP MNPs)| 7.9 ± 2.3<sup>a,b</sup>      | 18.9 ± 1.2<sup>b</sup>    | 1.5 ± 1.2<sup>a</sup>       |
| Group 6 (ESC + IT MNPs)| 10.9 ± 1.1<sup>b,c</sup>     | 8.9 ± 1.0<sup>a</sup>     | 1.0 ± 0.3<sup>a,b</sup>     |

All values are represented as mean ± standard error of mean (SE). There is a significant difference between groups by using one-way ANOVA at P < 0.05 followed by Duncan multiple comparison test. The same letter means that there is no significant difference between the two groups by using Duncan multiple comparison test (P > 0.05). The different letters mean that there is a significant difference between the two groups by using Duncan multiple comparison test (P < 0.05). *Statistically significant difference compared to negative control using Student’s t-test.

![Fig. 10](image-url) Effect of MNP injection on DNA damage induced in solid Ehrlich tumor and muscle tissues. *P < 0.05 vs non-treated control

© Springer
more than other organs as demonstrated by histopathological analysis [41].

Results here revealed that the liver, spleen, lung, and heart have significantly higher iron content in groups treated IP. While the tumor, muscles, and liver have significantly higher iron content in groups treated locally. Regarding to its effect on DNA, MNPs induced significant DNA damage in tumor injected locally. Significant DNA damage was induced in the liver in IP injected groups, but no significant DNA damage could be detected in the brain. Histopathological findings in ESC revealed marked tumor necrosis, 50% in IT injected group, 40% in IP injected group, and 20% only in untreated tumors. Other findings include inflammatory cell infiltration, dilatation, and congestion of blood vessels of different organs of treated groups in addition to appearance of metastatic cancer cells in the liver of non-treated tumor group.

During the experiment, lower activity and immobility of mice in tumor-bearing groups were observed due to development of solid tumor in the thigh. However, no other signs of toxicity were observed in all mice groups including weight loss, seizures, disheveled hair, irregular respiration, gastrointestinal symptoms, convulsions, severe decubitus paralysis, or death. Postmortem examination did not find significant changes in organ weights and morphology in all mice groups. The same observation was noticed in rat model administered with MNPs coated with meso-2, 3-dimercaptosuccinic acid (DMSA) and conjugated to PEG-derived molecules [29].

Herein, distribution of MNPs was detected by ICP measurements in various target organs and tissues. MNPs accumulated in tumor and muscle tissues comparably after IT and IM administration much more than after IP administration. The present results suggest that MNPs could successfully be uptaken by tumor tissues and more accumulated in tumor after IT injection, as a result of enhanced permeability and retention (EPR) in tumor tissue and the perforated leaky tumor-associated blood vessels which allow molecules to accumulate passively in the tumor microenvironment [42, 43]. Similarly, an earlier research showed that the concentrations of nanoparticles in cells affected by hematologic malignancy were much higher than those in normal somatocytes and can stay longer in blood [14, 44].

Furthermore, the liver, spleen, lung, and the heart showed significantly higher iron content in groups treated IP compared to control. Similar results have been observed for MNPs coated with PEG and dextran. Moreover, various

Table 4 Effect of MNP injection on DNA damage induced in brain tissues

| Groups          | Tail length (µm) (mean ± SE) | % DNA in tail (mean ± SE) | Tail moment (µm) (mean ± SE) |
|-----------------|------------------------------|---------------------------|------------------------------|
| Group 1 (control) | 3.9 ± 0.9 b                  | 6.1 ± 0.8 a               | 0.3 ± 0.4 a                  |
| Group 2 (IP MNPs) | 4.9 ± 0.6 a, b              | 6.05 ± 0.32 a            | 0.3 ± 0.2 a                  |
| Group 3 (IM MNPs) | 8.5 ± 1.9 a, b              | 8.3 ± 1.9 a              | 0.7 ± 0.2 a                  |
| Group 4 (ESC)     | 11.6 ± 2.2 a                | 6.6 ± 0.3 a              | 0.8 ± 1.2 a                  |
| Group 5 (ESC + IP MNPs) | 8.4 ± 2.9 ab              | 9.3 ± 1.7 a              | 0.8 ± 1.3 a                  |
| Group 6 (ESC + IT MNPs) | 8.1 ± 1.9 ab              | 8.7 ± 0.2 a              | 0.7 ± 0.7 a                  |

All values are represented as mean ± standard error of mean (SE). There is a significant difference between groups by using one-way ANOVA at $P < 0.05$ followed by Duncan multiple comparison test. The same letter means that there is no significant difference between the two groups by using Duncan multiple comparison test ($P > 0.05$). The different letters mean that there is a significant difference between the two groups by using Duncan multiple comparison test ($P < 0.05$).
studies have shown that MNPs have taken up by the reticuloendothelial system (RES) that is rich in macrophages including the liver (80–90%) and spleen (5–8%) [29, 45–49] more than in other organs including the brain, heart, kidney, and lungs [50, 51].

The liver showed much higher iron content than in tumor after IP injection which is similar to another study found that liver uptake for the MNPs is greater than for the tumor after intravenous injection [52]. On the other hand, groups treated locally have significantly higher iron content in the tumor, muscles, and liver with lower iron concentration in their other organs. This agrees with a previous study found that most of magnetic NPs, injected IT in mice model, remained in tumors and less than 1% of injected NPs were detected in the liver and spleen [49, 53]. Also, in a rat model of 9L-glioma, brain tumors administered PEG- magnetic NPs [47, 49]. It was reported that iron oxide nanoparticles ranging from 5 to 150 nm may offer the most effective distribution in certain tissues, especially in tumors [54, 55].

In the present study, groups of mice injected with Ehrlich tumor cells (4, 5, and 6) were injected with approximately the same number of cells (about 2 × 10⁶ cells) and showed the same tumor size at the beginning of experiment before treatment with MNPs without significant difference among groups. Interestingly, more necrotic effect of MNPs was observed on treated tumor compared to non-treated tumor. In addition, MNPs reduced metastasis in treated groups.

In the same context, a previous study reported a cell death and reduced proliferation of fibroblasts in vitro induced by uncoated MNPs and dextran-MNPs [11]. Also, uncoated SPIONS caused significant cell death in dermal fibroblasts, while lung cells were not affected [15, 56]. Another study found that magnetic iron oxide nanoparticles caused hyperthermia-mediated oncotic necrosis in head and neck cancer mouse model compared to non-treated tumors [13].

Histological examination was performed for injected sites and other organs (liver, spleen, kidney, lung, and brain) to look for signs of MNP accumulation and test their side effects on the other organs. It could be concluded that MNPs induced inflammatory responses with moderate toxicological effects in most of examined organs.

It is known that NPs can gain access to the nucleus and may induce DNA damage [57]. Herein, as detected by comet assay, MNPs induced a significant DNA damage in tumor injected locally. While a significant DNA damage was induced in the liver in groups that were injected IP, but no significant DNA damage was detected in the brain. Induced DNA damage may be attributed to free iron ions, those that catalyze the amplification of reactive oxygen species (ROS) and generation of highly reactive radicals through Fenton reactions [52]. MNPs coated with polyaspartic acid caused increase in micronucleus frequency in Swiss mice [21]. As well as MNPs caused high level of oxidative DNA lesions in A549 human lung epithelial cell line [58]. Furthermore, a concentration-dependent DNA damage was observed in SPION-treated L-929 fibroblasts cells [59]. Another study detected DNA damage induced by MNPs in Salmonella strains TA100, TA2638, TA102, and TA98 [60]. Cytotoxicity of superparamagnetic iron oxide nanoparticles was emphasized at several levels, including cellular changes such as oxidative stress-induced damage to nucleic acids and altered cellular responsiveness [61].

Conclusion

In conclusion, the present study has shown that MNPs may have antitumor effect on ESC grown subcutaneously in Swiss albino mice. Moreover, IT injection of MNPs is preferable to direct these NPs to tumor tissues and avoid their side effects on the normal tissues. This might be a good approach that opens a gate for new drug modality using nanotechnology.

Author Contribution HB performed the experiments, analyzed data, and wrote initial draft of the manuscript. AE, TSE, SS, and MM conceived, designed, planned, and supervised the study. HB, AE, TSE, SS, and MM analyzed and graphed data; interpreted results; and wrote, critically revised, and edited the manuscript. All authors read the final manuscript and approved submission.

Funding Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).

Data Availability The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics Approval The study protocol was approved by the Institutional Animal Care and Use Committee (IACUC), Faculty of Science, Cairo University, Egypt (approval number: CUF5/ F/ Cell Biol./ 02/ 13). All the experimental procedures were carried out in accordance with international guidelines for care and use of laboratory animals.

Consent to Participate Not applicable.

Consent for Publication Not applicable.

Competing Interests The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Lennart Treuel, X. J. (2013) New views on cellular uptake and trafficking of manufactured nanoparticles. Journal of the royal society, interface / the royal society 10

2. Khan I, Saeed K, Khan I (2019) Nanoparticles; properties, applications and toxicities. Arab J Chem 12:908–931

3. Kim JS, Yoon T-J, Yu KN, Kim BG, Park SJ, Kim HW, Lee KH, Park SB, Lee J-K, Cho MH (2006) Toxicity and tissue distribution of magnetic nanoparticles in mice. Toxicol Sci 89:338–347

4. Shubayev VI, Pisanic li TR, Jin S (2009) Magnetic nanoparticles for theragnostics. Adv Drug Deliv Rev 61:467–477

5. Malhotra N, Lee JS, Liman RAD, Ruallo JMS, Villaflorres OB, Ger TR, Hsiao CD (2020) Potential toxicity of iron oxide magnetic nanoparticles: a review. Molecules 25

6. Hofmann-Amtenbrink M, Von Rechenberg B, Hofmann H, Tan MC (2009) Superparamagnetic nanoparticles for biomedical applications

7. Xu C, Sun S (2013) New forms of superparamagnetic nanoparticles for biomedical applications. Adv Drug Deliv Rev 65:732–743

8. Ortega G, Reguera E (2019) Biomedical applications of magnetite nanoparticles. 397–434

9. Shen C-C, Liang H-J, Wang C-C, Liao M-H, Jan T-R (2012) Iron oxide nanoparticles suppressed T helper 1 cell-mediated immunity in a murine model of delayed-type hypersensitivity. International journal of nanomedicine 7

10. Suh WH, Suslick KS, Stucky GD, Suh Y-H (2009) Nanotechnology, nanotoxicology, and neuroscience. Prog Neurobiol 87:133–170

11. Berry CC, Wells S, Charles S, Curtis ASG (2003) Dextran and albumin derivatised iron oxide nanoparticles: influence on fibroblasts in vitro. Biomaterials 24:4551–4557

12. Szalay B (2012) Iron oxide nanoparticles and their toxicological effects: in vivo and in vitro studies, szte

13. Zhao Q, Wang L, Cheng R, Mao L, Arnold RD, Howerton EW, Chen ZG, Platt S (2012) Magnetic nanoparticle-based hyperthermia for head & neck cancer in mouse models. Theranostics 2

14. Wu W, Chen B, Cheng J, Wang J, Xu W, Liu L, Xia G, Wei H, Wang X, Yang M, Yang L, Zhang Y, Xu C, Li J (2010) Biocompatibility of Fe3O4/DNR magnetic nanoparticles in the treatment of hematologic malignancies. Int J Nanomed 5:1079–1084

15. Mahmoudi M, Hofmann H, Rothen-Rutishauser B, Petri-Fink A (2012) Assessing the in vitro and in vivo toxicity of superparamagnetic iron oxide nanoparticles. Chem Rev 112:2323–2338

16. Ma HL, Xu YF, Qi XR, Maitani Y, Nagai T (2008) Superparamagnetic iron oxide nanoparticles stabilized by alginate: pharmacokinetics, tissue distribution, and applications in detecting liver cancers. Int J Pharm 354:217–226

17. Park E-J, Kim H, Kim Y, Yi J, Choi K, Park K (2010) Inflammatory responses may be induced by a single intratracheal instillation of iron nanoparticles in mice. Toxicology 275:65–71

18. Szalay B, Tátrai E, Nyló G, Vezer T, Dura G (2012) Potential toxic effects of iron oxide nanoparticles in in vivo and in vitro experiments. J Appl Toxicol 32:446–453

19. Garcia MP, Miranda Parea R, Braun Chaves S, Paulino Silva L, Djalma Santos A, Lacava GM, Z., Cézar Morais, P., and Azevedo, R. B. (2005) Morphological analysis of mouse lungs after treatment with magnetite-based magnetic fluid stabilized with DMSA. J Magn Magn Mater 293:277–282

20. Singh N, Manshian B, Jenkins GJS, Griffiths SM, Williams PM, Maffeis TGG, Wright CJ, Doak SH (2009) NanoGenotoxicology: the DNA damaging potential of engineered nanomaterials. Biomaterials 30:3891–3914

21. Sadeghiani N, Barbosa LS, Silva LP, Azevedo RB, Morais PC, Lacava ZGM (2005) Genotoxicity and inflammatory investigation in mice treated with magnetite nanoparticles surface coated with polyaspartic acid. J Magn Magn Mater 289:466–468

22. Kabel AM (2014) Effect of combination between methotretate and histone deacetylase inhibitors on transplantable tumor model. Am J Med 2:12–18

23. Bassiony H, Sabet S, Salah El-Din TA, Mohamed MM, El-Ghor AA (2014) Magnetite nanoparticles inhibit tumor growth and upregulate the expression of p53/p16 in Ehrlich solid carcinoma bearing mice. PloS one 9, e111960

24. Salah El-Din TA, Bakr Mohamed M, Kamel HM, Abdel Kader M (2010) Magnetite nanoparticles as a single dose treatment for iron deficiency anemia. Innovative research and development co. (INRAD)

25. Fouad DM, Mohamed MB (2011) Photodegradation of chloridazon using coreshell magnetic nanocomposites. Journal of nanotechnology 2011

26. Mohamed AS, Hosnay M, Bassiony H, Hassanein SS, Soliman AM, Fahmy SR, Gaafat K (2020) Sodium pentobarbital dosages for exsanguination affect biochemical, molecular and histological measurements in rats. Sci Rep 10:378

27. Vicria J, Matsuzaki P, Nagamine MK, Haraguchi M, Akisue G, Gorniai SL, Dagli MLZ (2010) Inhibition of ascitic ehrlich tumor cell growth by intraperitoneal injection of Pfaffia paniculatula (Brazilian ginseng) butanolic residue. Braz Arch Biol Technol 53:609–613

28. Dagli MLZ, Guerra JL, Saldiva PHN (1992) An experimental study on the lymphatic dissemination of the solid Ehrlich tumor in mice. Braz j vet res anim sci 29:97–103

29. Ruiz A, Hernández Y, Cabal C, González E, Veintemillas-Verdaguer S, Martínez E, Morales MP (2013) Biodistribution and pharmacokinetics of uniform magnetite nanoparticles chemically modified with polyethylene glycol. Nanoscale 5

30. Costa R, Heinke D, Gruttner C, Westphal F, Morales MP, Veintemillas-Verdaguer S, Gehreke N (2019) Improving the reliability of the iron concentration quantification for iron oxide nanoparticle suspensions: a two-institutions study. Anal Bioanal Chem 411:1895–1903

31. Surendiran A, Sandhiya S, Pradhan SC, Adithan C (2009) Novel applications of nanotechnology in medicine. The Indian journal of medical research 130

32. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, Miyamae Y, Rojas E, Ryu JC, Sasaki YF (2000) Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 35:206–221

33. Chenthamara D, Subramaniam S, Ramakrishnan SG, Krishnaswamy S, Essa MM, Lin FH, Qoronekh MW (2019) Therapeutic efficacy of nanoparticles and routes of administration. Biomaterials research 23:20

34. Gurunathan S, Kang MH, Qasim M, Kim JH (2018) Nanoparticle-mediated combination therapy: two-in-one approach for cancer. International journal of molecular sciences 19

35. Klien K, Godnić-Cvar J (2012) Genotoxicity of metal nanoparticles: focus on in vivo studies. Arch Ind Hyg Toxicol 63:133–145

36. Shabatina TI, Vernayl OA, Shabatin VP, Melnikov YV (2020) Magnetic nanoparticles for biomedical purposes: modern trends and prospects. Magnetochromev 6:30
37. Hosu T, Cristea. (2019) Implication of magnetic nanoparticles in cancer detection, screening and treatment. Magnetochemistry 5:55
38. Lubbe AS, Bergemann C, Huhnt W, Fricke T, Riess H, Brock JW, Huhn D (1996) Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res 56
39. Prijic S, Sersa G (2011) Magnetic nanoparticles as targeted delivery systems in oncology. raon 45, 1–16
40. Aras O, Pearce G, Watkins AJ, Nurili F, Medine EI, Guldu OK, Tekin V, Wong J, Ma X, Ting R, Unak P, Akin O (2018) An in vivo pilot study into the effects of FDG-mNP in cancer in mice. PloS one 13, e0202482
41. Prabu P, Vedakumari WS, Sastry TP (2015) Time-dependent biodistribution, clearance and biocompatibility of magnetic fibrin nanoparticles: an in vivo study. Nanoscale 7:9676–9685
42. Subhan MA, Yalamarty SSK, Filipczak N, Parveen F, Torchilin VP (2021) Recent advances in tumor targeting via EPR effect for cancer treatment. Journal of personalized medicine 11
43. Golombek SK, May JN, Theek B, Appold L, Drude N, Kiessling F, Lammers T (2018) Tumor targeting via EPR: strategies to enhance patient responses. Adv Drug Deliv Rev 130:17–38
44. Cheng Jian WW (2009) Effect of magnetic nanoparticles of Fe3O4 and 5-bromotetrandrine on reversal of multidrug resistance in K562/A02 leukemic cells. International journal of nanomedicine
45. Chen B (2010) Pharmacokinetic parameters and tissue distribution of magnetic Fe3O4 nanoparticles in mice. International journal of nanomedicine
46. Shen C-C, Wang C-C, Liao M-H, Jan T-R (2011) A single exposure to iron oxide nanoparticles attenuates antigen-specific antibody production and T-cell reactivity in ovalbumin-sensitized BALB/c mice. International journal of nanomedicine 6
47. Cole AJ, David AE, Wang J, Galbán CJ, Yang VC (2011) Magnetic brain tumor targeting and biodistribution of long-circulating PEG-modified, cross-linked starch-coated iron oxide nanoparticles. Biomaterials 32:6291–6301
48. Neuberger T, Schöpf B, Hofmann H, Hofmann M, von Rechenberg B (2005) Superparamagnetic nanoparticles for biomedical applications: possibilities and limitations of a new drug delivery system. J Magn Magn Mater 293:483–496
49. Varna M (2012) In vivo distribution of inorganic nanoparticles in preclinical models. Journal of biomaterials and nanobiotechnology 03:269–279
50. Jain TK, Reddy MK, Morales MA, Leslie-Pelecky DL, Labhasetwar V (2008) Biodistribution, clearance, and biocompatibility of iron oxide magnetic nanoparticles in rats. Mol Pharmaceutics 5:316–327
51. Barua S, Mitragotri S (2014) Challenges associated with penetration of nanoparticles across cell and tissue barriers: a review of current status and future prospects. Nano Today 9:223–243
52. Hainfeld J, Huang (2013) Intravenous magnetic nanoparticle cancer hyperthermia. International journal of nanomedicine
53. Kettering M, Richter H, Wiekhorst F, Bremer-Streck S, Trahms L, Kaiser WA, Hilger I (2011) Minimal-invasive magnetic heating of tumors does not alter intra-tumoral nanoparticle accumulation, allowing for repeated therapy sessions: an in vivo study in mice. Nanotechnology 22
54. Gupta AK, Gupta M (2005) Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26:3995–4021
55. Peng X-H, Qian X, Mao H, Wang AY (2008) Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. International journal of nanomedicine
56. Markides H, Rotherham M, El Haj AJ (2012) Biocompatibility and toxicity of magnetic nanoparticles in regenerative medicine. Journal of nanomaterials 2012
57. Rim KT, Song SW, Kim HY (2013) Oxidative DNA damage from nanoparticle exposure and its application to workers’ health: a literature review. Saf Health Work 4:177–186
58. Singh N, Jenkins GJS, Asadi R, Doak SH (2010) Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION). Nano reviews 1
59. Hong SC, Lee JH, Lee J, Kim HY, Park JY, Cho J, Lee J, Han D-W (2011) Subtle cytotoxicity and genotoxicity differences in superparamagnetic iron oxide nanoparticles coated with various functional groups. International journal of nanomedicine 6
60. Gomaa IO, Kader MH, Salah TA, Heikal OA (2013) Evaluation of in vitro mutagenicity and genotoxicity of magnetite nanoparticles. Drug discoveries & therapeutics 7:116–123
61. Patil RM, Thorat ND, Shete PB, Bedge PA, Gavde S, Joshi MG, Tofail SAM, Bohara RA (2018) Comprehensive cytotoxicity studies of superparamagnetic iron oxide nanoparticles. Biochemistry and biophysics reports 13:63–72

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.